A Digital Publication for the Practicing Medical Specialist, Industry Executive and Investor
Medical Device News Magazine is committed to delivering high‑quality, in‑depth medical device news and biotechnology updates that include expert bylines. Our coverage offers a comprehensive view of the trends, innovations, and breakthroughs shaping the future of medical technology.
We also strive to provide a distinctive perspective on the rapidly evolving healthcare landscape. By staying connected with our reporting, you gain access to exclusive insights on industry developments, emerging technologies, and global regulatory changes that influence the medical device sector. At the same time, you join a vibrant community of professionals, innovators, and thought leaders dedicated to advancing healthcare through cutting‑edge solutions.
We invite you to explore our wide range of content—from the latest product announcements to detailed analyses of industry trends. And if our mission aligns with your goals, we offer opportunities for advertising and collaboration, helping you connect with a highly engaged audience of medical technology professionals.
Definition medical devices.
AcuityMD’s data and insights drive commercial growth of important new option to families seeking alternatives for routine ear tube placement in millions of children
Archetype teams with LumipenPro™ to enhance early-stage medical device innovation through its new investment partnership
Driven by AESOP Technology’s Clinical Deep Reasoning Network Model, DxPrime customizes its insights based on specialty, gender, and clinical context to ensure diagnostic completeness and precision
Material choice is inseparable from the manufacturing process and the partner who will make your parts at scale. By prioritizing the key criteria, you reduce risk and speed validation. Choose a partner to move from uncertainty to certifiable results
Vertex Pulmonary Embolectomy System demonstrated significant right heart recovery, low adverse event rates, and reproducible performance across high-severity PE patients
Full data presented at ESOC 2026 further strengthen the clinical evidence supporting TIGERTRIEVER™ 13 for the treatment of distal vessel occlusion stroke — a segment representing nearly half of all ischemic strokes
The technology is customized to each patient’s breast and tumor via 3D printing
“By integrating Oxford Nanopore’s direct RNA sequencing into Lonza’s QC environment, we are enabling a more comprehensive and scalable approach to mRNA quality control,” said Francis Van Parys, CEO, Oxford Nanopore Technologies
Collaboration integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights’ curated biomedical knowledge bases
This evolution formalizes Mopec Group's commitment to developing integrated, technology-driven solutions that enhance how pathology laboratories document, manage, and move through the diagnostic workflow
Michael Harris, Chief Executive Officer of Biocomposites, said: “Periprosthetic joint infection is a large and growing problem worldwide. Quickly and accurately pinpointing the bacteria that cause each infection is essential if patients are to receive the best care and maximise their chances of full recovery.
Use of proceeds from the Series B financing will support the clinical entry and development of RTX001, with a Phase I/II trial expected to start in Q4 CY2024. Following this financing, Resolution Therapeutics is funded to deliver data from this trial, anticipated in CY2026, a key value inflection point with the potential to drive significant NAV growth for Syncona. Proceeds will also be used to develop the company’s manufacturing platform, expand the pre-clinical pipeline, and further strengthen the management team, following several key recent appointments, including Dr Amir Hefni as CEO, Simon Ramsden as CFO and Dr Clifford A. Brass as CMO.
Celaid Therapeutics secures up to approx. $19M non-dilutive grant funding from Japanese government. The grant funding will support the development of Celaid’s hematopoietic stem cell product for pediatric non-malignant diseases.
According to According to Pila Pharma, the capital raised will support the study with the objective to assess the molecule’s safety in increased dosages, as well as to expand on the number of study participants to determine, though empirical statistical calculations, whether the molecule has potential as part of a new tablet-based obesity treatment., the capital raised will support the study with the objective to assess the molecule’s safety in increased dosages, as well as to expand on the number of study participants to determine, though empirical statistical calculations, whether the molecule has potential as part of a new tablet-based obesity treatment.
The integration of AI in biopharma workflows is not just a technological advancement, but a paradigm shift that promises to completely revolutionize how we research, understand, and treat diseases. Read what this expert has to say.
Artificial intelligence provides a simpler and faster alternative and could be a potential game-changer for their heart patients. For example, HeartFlow’s AI-enabled Plaque Analysis tool leverages an automated, deep learning-based, non-invasive method for identifying, characterizing, and segmenting plaque throughout the coronary arteries. By offering a more comprehensive view, plaque analysis tools can improve diagnostic accuracy, enhance treatment planning, and help stratify risk.
Explore how the intersection of medical device design and disruptive technologies is reshaping the healthcare industry. Discover how new players armed with AI-driven devices and advanced manufacturing tools are pushing boundaries and revolutionizing the future of medical innovation. Steve Levine, Senior Director at Dassault Systèmes, shares insights on the next plateau of medical device design.
In brain health, traditional inpatient monitoring systems present a myriad of barriers. They often require travel to a specialized health center, are cumbersome and restrictive for patients, and technical requirements and limitations impede providers’ ability to even provide such services. Today, advancements are disrupting this model to fuel the growth of person-enabled health and the ongoing treatment of chronic neurological disorders and conditions
This new clearance broadens the clinical utility of the Restrata platform, now supporting soft tissue reinforcement applications in addition to its previously cleared indications for wound healing. This clearance applies to both Restrata Sheet and Restrata Meshed products.
This designation reflects Sanofi’s commitment to addressing a critical unmet need in transplant medicine, where AMR remains a significant challenge with no FDA-approved treatments available.
Dr. Park is a former principal investigator for the SynerFuse® proof-of-concept study and primary inventor of SynerFuse® technology.
Clinilabs, LLC, a leading full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and medical technology development, today announced the appointments of
Mr. Demetri brings over 20 years of experience in healthcare technology, with a track record of advancing AI adoption in complex clinical settings.
Charlie Minutella brings a wealth of industry knowledge and a strong track record of leadership, innovation, and operational excellence. His appointment ushers in a new chapter for RapidRatings as it continues to shape the future of financial risk intelligence.
New supply contract to bring Lunit INSIGHT CXR to TeleDiag in France and Lunit INSIGHT MMG to the Central region branch of the Portuguese League Against Cancer
KA Imaging reported a collection of positive metrics to its stakeholders, with revenue four times larger than that of the previous year and a 38% growth in headcount in 2023. The positive trend continues to be observed in Q1 2024.
Isaac Zaworski, President of Sectra advises: “Collaborating across sites and providing efficient radiology workflows are needed to cope with the increasing imaging volumes. This new customer is the 60th healthcare provider to use Sectra in the US Midwest and I’m pleased to be continuing our work in this area. With our local experience as well as our knowledge in providing multi-site solutions for large organizations we will help them on this journey in the best way possible.”
MediView notes the system, which has received 510(k) clearance from the U.S. Food and Drug Administration and is currently in clinical use, is intended to be used adjunctively for minimally invasive ultrasound guided needle-based procedures for soft tissue and bone.
Professionals can find help that fits their needs, making mental healthcare easier to access than ever before.
Launch your site with local website design & development services that convert visitors into paying customers. Stop settling for “good enough.” Get a website that works as hard as you do
MRI scan volumes are growing fast, but are your reporting workflows keeping up? In many diagnostic clinics today, the challenge isn’t just capturing high-quality images
Insurance verification is a critical part of the process to ensure patients get their durable medical equipment they need on time.
